RSM offers additional support to Anthony Nolan’s lifesaving couriers

May 27, 2016
Category
For the latest data and information, visit our Facts & Stats page

Anthony Nolan has unveiled the RSM-sponsored kit that will be used by its team of couriers to transport lifesaving stem cells around the world. RSM is one of the leading accounting and business advisory firms in the UK and has proudly supported the charity for many years.  

Anthony Nolan facilitates three potentially lifesaving transplants every day, using a team of around 50 volunteer couriers to carry stem cells to wherever they are needed in the world. With only a 72-hour window for the stem cells to be transplanted, often it’s a race against time for the couriers to ensure the cells arrive safely and on time. Between September 2015 and March 2016, the couriers made over 500 journeys, both across the UK and to worldwide destinations including Australia and Canada.

The courier team has been supplied with RSM-branded kit, as well as smartphones installed with Guardian24 (G24) which will help them carry out their duties more safely and allow them to raise an emergency alarm at the touch of a button in any country. The system will also inform Anthony Nolan once the courier has arrived home safely after delivering cells.

 

A lifesaving partnership

Martin Rodgers, RSM’s Chairman, said:

‘The Anthony Nolan couriers selflessly give up their time to carry lifesaving cells to recipients wherever they are in the world, and as a result, these individuals have helped save countless lives over the years.

‘I’m delighted that we can support them and show our appreciation for the important work they do in making a difference to the lives of so many people and their families.’

Laura Parsell, Anthony Nolan’s Head of Corporate Partnerships, said:

‘RSM are one of our most committed and longstanding corporate partners and we are proud to be their chosen charity. We are so grateful for RSM’s continued generosity which plays a crucial part in our work saving the lives of people with blood cancer.’